The diabetes drug metformin is being used in some cancer treatment trials, but study results show the use of metformin does not improve survival of patients with pancreatic ductal adenocarcinoma.
Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma (PDAC) in a retrospective cohort study, according to data presented here at the American Association for Cancer Research Annual Meeting 2015, April 18-22.
“The diabetes drug metformin is being used in some cancer treatment trials based on epidemiologic studies that have reported that use of metformin reduces the risk of death from cancer,” said Roongruedee Chaiteerakij, MD, PhD, of the Division of Gastroenterology and Hepatology at Mayo Clinic Cancer Center in Rochester, Minnesota. “This study highlights the importance of appropriate design of retrospective studies and the necessity of conducting prospective studies with solid rationale for determining the effect of diabetes drugs on cancer risk or death.”
Read the press release: http://bit.ly/1HRx3gh
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More